Status:
UNKNOWN
Intestinal Microbiota and Treatment of GD
Lead Sponsor:
First Affiliated Hospital of Harbin Medical University
Conditions:
Microbiota
Eligibility:
All Genders
18-65 years
Brief Summary
Graves' disease is an organ-specific autoimmune disease in which both genetic predisposition and environmental factors serve as disease triggers. Many studies have indicated that alterations in the gu...
Detailed Description
Graves' disease is an organ-specific autoimmune disease in which both genetic predisposition and environmental factors serve as disease triggers. Many studies have indicated that alterations in the gu...
Eligibility Criteria
Inclusion
- Aged 18 to 65 years
- GD was clinical diagnosed and accept the standard treatment of methimazole or propylthiouracil and thyroid function returned to normal
Exclusion
- Pregnancy
- Lactation
- Cigarette smoking
- Alcohol addiction
- Hypertension
- Diabetes mellitus
- Lipid dysregulation
- BMI \> 27
- Recent (\< 3 months prior) use of antibiotics, probiotics, prebiotics, symbiotics, hormonal medication, laxatives, proton pump inhibitors, insulin sensitizers or Chinese herbal medicine
- History of disease with an autoimmune component, such as MS, rheumatoid arthritis, IBS, or IBD
- History of malignancy or any gastrointestinal tract surgery
Key Trial Info
Start Date :
December 23 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 20 2019
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT03433352
Start Date
December 23 2017
End Date
December 20 2019
Last Update
February 14 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First affiliated hospital of Harbin medical university
Harbin, Heilongjiang, China, 150001